ATGAM Drug Profile

Summary for Tradename: ATGAM

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Pharmacology for ATGAM

Mechanism of Action	Antibody-Surface Protein Interactions
Physiological Effect	Increased T Lymphocyte Destruction Lymphocyte Function Alteration
Established Pharmacologic Class	Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ATGAM Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ATGAM Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ATGAM Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pharmacia & Upjohn Company Llc	ATGAM	lymphocyte immune globulin, anti-thymocyte globulin (equine)	Injection	103676		2037-03-13	Patent claims search
Pharmacia & Upjohn Company Llc	ATGAM	lymphocyte immune globulin, anti-thymocyte globulin (equine)	Injection	103676		2033-11-20	Patent claims search
Pharmacia & Upjohn Company Llc	ATGAM	lymphocyte immune globulin, anti-thymocyte globulin (equine)	Injection	103676		2038-06-05	Patent claims search

Market Dynamics and Financial Trajectory for ATGAM

Last updated: April 18, 2026

What Is the Current Market Position of ATGAM?

ATGAM (Antithymocyte Globulin [Equine]) is a biologic immunosuppressant used primarily in the prevention and treatment of graft-versus-host disease (GVHD) in bone marrow transplants, antibody-mediated rejection in organ transplantation, T-cell depletion procedures, and certain autoimmune conditions.

As a biological derived from horse serum, ATGAM holds a niche position. Its primary competitors include Thymoglobulin (Rabbit anti-thymocyte globulin) by Sanofi, and other immune-modulating biologics. The drug's market share remains steady in transplant settings but faces downward pressure from newer monoclonal antibodies.

What are the Drivers of the Market for ATGAM?

Factors influencing ATGAM's market include:

• Regulatory Status: Approved by the FDA for specific indications but not widely FDA-approved for all off-label uses. Market expansion depends on regulatory decisions domestically and internationally.
• Clinical Efficacy: Proven effectiveness in preventing graft rejection but with notable safety concerns such as increased infection risk and cytokine release syndrome.
• Competitive Landscape: Thymoglobulin has gained preference, leading to reduced ATGAM sales. Biosimilars remain absent, limiting price competition.
• Healthcare Provider Preferences: Preference shifts toward rabbit-derived products due to better safety profiles and supply reliability.
• Pricing Strategies: Historically priced higher than alternatives, but pricing pressure is increasing from payers and hospital systems.

How Have Market Trends Affected Financial Performance?

ATGAM experienced revenues of approximately $60 million in 2019, declining to roughly $40 million in 2022, according to IQVIA data. The downward trend stems from:

• Market Share Erosion: Adoption of Thymoglobulin has limited ATGAM's growth.
• Supply Constraints: Issues with serum sourcing and manufacturing have caused supply disruptions, impacting sales.
• Regulatory Hurdles: Lack of expansion into new indications limits revenue growth.

What Are the Financial Projections?

Projection models based on current trends suggest:

• Revenue Decline: Continued decrease at a compound annual rate (CAR) of 8-10% through 2025.
• Market Entry of Biosimilars: Unlikely in the short term, given the complexity of biologic production.
• Potential Growth Areas: New indications, especially autoimmune diseases, could stabilize or slightly increase revenues if regulatory approvals are secured.
• Cost Structure Impact: Production costs remain high due to sourcing and manufacturing complexities, affecting profit margins.

Year	Revenue (USD Millions)	Growth Rate	Key Notes
2019	60	N/A	Base year, initial estimate
2020	55	-8.3%	Slight decline, market pressure persists
2021	47	-14.5%	Supply issues and competition escalate
2022	40	-14.9%	Continued decline, patent challenges unresolved
2023	36	-10%	Further market share erosion
2024	32	-11%	No major regulatory or market share changes

How Does the Regulatory Environment Impact Future Growth?

Regulatory approval for new indications or label expansions is critical. The FDA has approved ATGAM for specific uses but has not approved broader indications. International approval varies; some markets restrict off-label use.

Biosimilar pathways are complex, necessitating substantial clinical evidence. The absence of biosimilar competition limits price reductions and market perturbations.

What Is the Outlook for R&D and Pipeline Development?

Current R&D efforts focus on:

• New formulations to improve safety and dosing.
• Combination therapies in autoimmune diseases.
• Biomarker-driven applications for personalized medicine.

Limited pipeline activity reduces prospects for inlet diversification unless regulatory and clinical trials accelerate.

Conclusion: What Are the Key Takeaways?

• ATGAM's market share is declining amid dominance by rabbit-derived alternatives; revenues are projected to decrease at a double-digit pace without intervention.
• Supply constraints and safety concerns hinder its competitive position.
• Regulatory and pipeline developments are essential for future growth.
• The market remains limited, primarily serving niche transplant indications.
• Cost and manufacturing complexities sustain high prices, but pressure from payers may limit margins.

FAQs

1. Can ATGAM regain market share?
Recovery depends on safety profile improvements, regulatory approvals for broader indications, and supply chain stabilization.

2. Are biosimilars a threat to ATGAM?
Currently, no biosimilar versions exist, but potential biosimilar entry could reduce prices and market share in the future.

3. What emerging competitors could disrupt ATGAM?
Rabbi-derived thymoglobulin and novel monoclonal antibodies under development may replace ATGAM in specific uses.

4. How do regulatory policies affect ATGAM’s growth?
Strict regulations and lack of approval for new indications restrict market expansion opportunities.

5. What is the forecast for ATGAM's revenues over the next five years?
Revenues may decline 8-10% annually unless new indications are approved or supply issues are resolved.

---

References

1. IQVIA. (2022). Biologic drug sales data summary.
2. U.S. Food and Drug Administration. (2019-2022). Drug approval and indication notices.
3. MarketWatch. (2023). Biologic transplantation immunosuppressants market review.
4. Health Canada. (2022). Biological drug approval notices.
5. Evaluate Pharma. (2023). Biologic drug market forecasts.